234 related articles for article (PubMed ID: 31079358)
1. Effect of Intravitreal Anti-Vascular Growth Factor Agents With or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
Cui L; Jiao B; Han Q
Diabetes Ther; 2019 Aug; 10(4):1283-1296. PubMed ID: 31079358
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: A systematic review and network meta-analysis.
Chen J; Wang H; Qiu W
Front Endocrinol (Lausanne); 2023; 14():1096105. PubMed ID: 36817588
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis.
Liu XD; Zhou XD; Wang Z; Shen HJ
Int J Ophthalmol; 2014; 7(6):1048-55. PubMed ID: 25540764
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Agents and Corticosteroids in Managing Diabetic Retinopathy-Associated Diabetic Macular Edema: A Meta-Analysis and Comprehensive Systematic Review.
Kumar A; Kumar A; Kumar J; Bai G; Jeewnani R; Dembra M; Kanwal K; Qadeer U; Khawar MH; Yaseen Khan I; Ram R; Varrassi G
Cureus; 2024 Jan; 16(1):e51910. PubMed ID: 38333510
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
7. Response to Initial Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema Is Significantly Correlated with Response to Third Consecutive Monthly Injection.
Maeda S; Sugimoto M; Tenma Y; Tsukitome H; Kato K; Chujo S; Matsui Y; Matsubara H; Kondo M
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362644
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials.
Wang H; Sun X; Liu K; Xu X
Curr Eye Res; 2012 Aug; 37(8):661-70. PubMed ID: 22631452
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: A meta-analysis.
Xu D; Zhu T; Huang L; Wang X; Chen M
Medicine (Baltimore); 2024 Feb; 103(5):e34583. PubMed ID: 38306515
[TBL] [Abstract][Full Text] [Related]
11. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intravitreal Bevacizumab with or without Macular Photocoagulation for Diabetic Macular Edema: A Meta-Analysis.
Xiao K; Weng SJ; Liang SZ; Wang J; Qian C; Wan GM
Diabetes Ther; 2018 Dec; 9(6):2369-2381. PubMed ID: 30390227
[TBL] [Abstract][Full Text] [Related]
13. Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
Maloney MH; Schilz SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2019 Jul; 126(7):1007-1015. PubMed ID: 30292542
[TBL] [Abstract][Full Text] [Related]
14. Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
Maggio E; Sartore M; Attanasio M; Maraone G; Guerriero M; Polito A; Pertile G
Am J Ophthalmol; 2018 Nov; 195():209-222. PubMed ID: 30098350
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
Faghihi H; Roohipoor R; Mohammadi SF; Hojat-Jalali K; Mirshahi A; Lashay A; Piri N; Faghihi Sh
Eur J Ophthalmol; 2008; 18(6):941-8. PubMed ID: 18988166
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Ollendorf DA; Colby JA; Pearson SD
Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
Liu Y; Cheng J; Gao Y; Qin L; Min X; Zhang M
Ann Transl Med; 2020 Mar; 8(6):382. PubMed ID: 32355826
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice.
Gurung RL; FitzGerald LM; Liu E; McComish BJ; Kaidonis G; Ridge B; Hewitt AW; Vote BJ; Verma N; Craig JE; Burdon KP
Int J Retina Vitreous; 2023 Apr; 9(1):23. PubMed ID: 37016462
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
